Research Analysts Issue Forecasts for NAMS FY2024 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for NewAmsterdam Pharma in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($1.77) per share for the year, up from their previous estimate of ($2.02). The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s Q4 2024 earnings at ($0.46) EPS, FY2025 earnings at ($1.50) EPS, FY2026 earnings at ($1.40) EPS and FY2027 earnings at ($1.45) EPS.

NAMS has been the topic of several other research reports. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, November 7th. Piper Sandler reissued an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma has an average rating of “Buy” and a consensus target price of $33.80.

NewAmsterdam Pharma Trading Up 1.9 %

Shares of NAMS opened at $24.59 on Monday. The stock has a fifty day moving average price of $17.83 and a two-hundred day moving average price of $18.50. NewAmsterdam Pharma has a 52-week low of $8.64 and a 52-week high of $26.35.

Insider Activity

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 19.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently made changes to their positions in the business. Banque Cantonale Vaudoise acquired a new stake in NewAmsterdam Pharma in the 2nd quarter valued at $38,000. Rosalind Advisors Inc. bought a new position in NewAmsterdam Pharma in the second quarter valued at approximately $194,000. Wolverine Asset Management LLC increased its position in shares of NewAmsterdam Pharma by 117.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after purchasing an additional 8,394 shares during the last quarter. Sei Investments Co. raised its stake in shares of NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after purchasing an additional 8,087 shares in the last quarter. Finally, Lisanti Capital Growth LLC bought a new position in shares of NewAmsterdam Pharma in the third quarter valued at $700,000. 89.89% of the stock is owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.